Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Hyperkalaemia is a frequent, life-threatening complication in heart failure (HF).
• It is often associated with cardiac dysfunction and arrhythmia.
• Managing hyperkalaemia is crucial for patients on renin-angiotensin-aldosterone system inhibitors, angiotensin receptor-neprilysin inhibitors, and mineralocorticoid receptor antagonists.

Purpose of the Study:

• To evaluate the prevalence of hyperkalaemia in heart failure patients.
• To review novel therapeutic approaches for managing hyperkalaemia in HF.
• To assess the role of hyperkalaemia management in optimizing guideline-directed medical therapy.

Main Methods:

• Review of recent epidemiological data on hyperkalaemia in HF.
• Analysis of pathomechanisms and clinical implications of hyperkalaemia.
• Evaluation of novel potassium-binding agents and their safety/efficacy profiles.

Main Results:

• Novel potassium binders (e.g., patiromer, sodium zirconium cyclosilicate) are effective and well-tolerated.
• Older potassium binders were associated with serious adverse events.
• Hyperkalaemia serves as a biomarker for disease severity and neurohormonal activation.

Conclusions:

• Novel potassium binders offer a safe and effective strategy for managing hyperkalaemia in HF.
• Optimizing hyperkalaemia treatment can facilitate the use of life-saving HF therapies.
• Effective management of hyperkalaemia is essential for improving cardiovascular outcomes in HF patients.